Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD
Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 16.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,025,000 shares of the biopharmaceutical company's stock after selling 2,975,000 shares during the period.
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion.
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock?
Amicus stock soars 135.8% in six months as demand for marketed products grows. The company is set to be acquired by BioMarin for $4.8 billion.
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock?
Amicus hits a 52-week high after an 87.6% six-month surge, driven by strong Galafold sales and rising uptake of Pombiliti + Opfolda.
Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High?
The consensus price target hints at a 60.6% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Best Cheap Stocks Under $10 to Buy in December and 2026
Today, we explore how investors can find the best-in-class cheap stocks trading for under $10 a share to buy now.
Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Galafold Continue to Drive Amicus' Top Line in 2026?
FOLD leans on rising Galafold sales on the back of strong commercial execution as momentum builds into 2026.
Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
